|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics 2018. CA Cancer J Clin. 68:284–296. 2018.
View Article : Google Scholar
|
|
2
|
Li X and Wang X: The emerging roles and
therapeutic potential of exosomes in epithelial ovarian cancer. Mol
Cancer. 16:922017. View Article : Google Scholar
|
|
3
|
Moufarrij S, Dandapani M, Arthofer E,
Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli
KB: Epigenetic therapy for ovarian cancer: Promise and progress.
Clin Epigenetics. 11:72019. View Article : Google Scholar
|
|
4
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar
|
|
5
|
Peng WX, Koirala P and Mo YY:
lncRNA-Mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar
|
|
6
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar
|
|
7
|
Chen J, Yu Y, Li H, Hu Q, Chen X, He Y,
Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes
tumor progression by regulating the miR-143/HK2 axis in gallbladder
cancer. Mol Cancer. 18:332019. View Article : Google Scholar
|
|
8
|
Luo Y, Chen JJ, Lv Q, Qin J, Huang YZ, Yu
MH and Zhong M: Long non-coding RNA NEAT1 promotes colorectal
cancer progression by competitively binding miR-34a with SIRT1 and
enhancing the wnt/β-catenin signaling pathway. Cancer Lett.
440:11–22. 2019. View Article : Google Scholar
|
|
9
|
Sun K, Jia Z, Duan R, Yan Z, Jin Z, Yan L,
Li Q and Yang J: Long non-coding RNA XIST regulates miR-106b-5p/P21
axis to suppress tumor progression in renal cell carcinoma. Biochem
Biophys Res Commun. 510:416–420. 2019. View Article : Google Scholar
|
|
10
|
Tripathi MK, Doxtater K, Keramatnia F,
Zacheaus C, Yallapu MM, Jaggi M and Chauhan SC: Role of lncRNAs in
ovarian cancer: Defining new biomarkers for therapeutic purposes.
Drug Discov Today. 23:1635–1643. 2018. View Article : Google Scholar
|
|
11
|
Nikpayam E, Tasharrofi B, Sarrafzadeh S
and Ghafouri-Fard S: The role of long non-coding RNAs in ovarian
cancer. Iran Biomed J. 21:3–15. 2017. View Article : Google Scholar
|
|
12
|
Zhang T, Cao C, Wu D and Liu L: SNHG3
correlates with malignant status and poor prognosis in
hepatocellular carcinoma. Tumour Biol. 37:2379–2385. 2016.
View Article : Google Scholar
|
|
13
|
Hong L, Chen W, Wu D and Wang Y:
Upregulation of SNHG3 expression associated with poor prognosis and
enhances malignant progression of ovarian cancer. Cancer Biomark.
22:367–374. 2018. View Article : Google Scholar
|
|
14
|
Li N and Zhan X and Zhan X: The lncRNA
SNHG3 regulates energy metabolism of ovarian cancer by an analysis
of mitochondrial proteomes. Gynecol Oncol. 150:343–354. 2018.
View Article : Google Scholar
|
|
15
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar
|
|
16
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs, Bell
GW, Jin WN and David PB: Predicting effective microRNA target sites
in mammalian mRNAs. eLife. 4:e050052015. View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCq method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
18
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar
|
|
19
|
Kossaï M, Leary A, Scoazec JY and Genestie
C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49.
2017. View Article : Google Scholar
|
|
20
|
Zhang HD, Jiang LH, Sun DW, Li J and Tang
JH: miR-139-5p: Promising biomarker for cancer. Tumor Biol.
36:1355–1365. 2015. View Article : Google Scholar
|
|
21
|
Yang B, Zhang W, Sun D, Wei X, Ding Y, Ma
Y and Wang Z: Downregulation of miR-139-5p promotes prostate cancer
progression through regulation of SOX5. Biomed Pharmacother.
109:2128–2135. 2019. View Article : Google Scholar
|
|
22
|
Wang K, Jin J, Ma T and Zhai H: miR-139-5p
inhibits the tumorigenesis and progression of oral squamous
carcinoma cells by targeting HOXA9. J Cell Mol Med. 21:3730–3740.
2017. View Article : Google Scholar
|
|
23
|
Agosta C, Laugier J, Guyon L, Denis J,
Bertherat J, Libé R, Boisson B, Sturm N, Feige JJ, Chabre O and
Cherradi N: miR-483-5p and miR-139-5p promote aggressiveness by
targeting N-myc downstream-regulated gene family members in
adrenocortical cancer. Int J Cancer. 143:944–957. 2018. View Article : Google Scholar
|
|
24
|
Wang Y, Li J, Xu C and Zhang X:
MicroRNA-139-5p inhibits cell proliferation and invasion by
targeting RHO-associated coiled-coil-containing protein kinase 2 in
ovarian cancer. Oncol Res. 26:411–420. 2018. View Article : Google Scholar
|
|
25
|
Liu X, Li Y, Wen J, Qi T and Wang Y: Long
non-coding RNA TTN-AS1 promotes tumorigenesis of ovarian cancer
through modulating the miR-139-5p/ROCK2 axis. Biomed Pharmacother.
125:1098822020. View Article : Google Scholar
|
|
26
|
Huang Y: The novel regulatory role of lnc
RNA-mi RNA-mRNA axis in cardiovascular diseases. J Cell Mol Med.
22:5768–5775. 2018. View Article : Google Scholar
|
|
27
|
Brzozowa-Zasada M, Piecuch A, Dittfeld A,
Mielańczyk Ł, Michalski M, Wyrobiec G, Harabin-Słowińska M, Kurek J
and Wojnicz R: Notch signalling pathway as an oncogenic factor
involved in cancer development. Contemp Oncol (Pozn). 20:267–272.
2016.
|
|
28
|
Alniaimi AN, Demorest-Hayes K, Alexander
VM, Seo S, Yang D and Rose S: Increased notch1 expression is
associated with poor overall survival in patients with ovarian
cancer. Int J Gynecol Cancer. 25:208–213. 2015. View Article : Google Scholar
|
